Personalized smoking cessation: Interactions between nicotine dose, dependence and quit-success genotype score

Molecular Medicine

Volumn 16, Issue 7-8, 2010, Pages 247-253

  Rose, Jed E ^a   Behm, Frédérique M ^a   Drgon, Tomas ^b   Johnson, Catherine ^b   Uhl, George R ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NICOTINE PATCH; PLACEBO; DELAYED RELEASE FORMULATION; NICOTINE;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SMOKING CESSATION; SYNCOPE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VIVID DREAM; VOMITING; DELAYED RELEASE FORMULATION; GENETIC ASSOCIATION; GENETICS; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TOBACCO USE DISORDER;

ADMINISTRATION, CUTANEOUS; ADULT; CARBON MONOXIDE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 77954267769     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00159     Document Type: Article

References (38)

1. Adhikari B, Kahende J, Malarcher A, Pechacek T, Tong V. (2008) Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMVR Wkly. 57:1226-8.
2. Godtfredsen NS, et al. (2008) COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur. Respir. J. 32:844-53.
3. Teo KK, et al. (2006) Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 368:647-58.
4. White WB. (2007) Smoking-related morbidity and mortality in the cardiovascular setting. Prev. Cardiol. 10:1-4.
5. Moore D, et al. (2009) Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and metaanalysis. BMJ. 338:b1024.
6. Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ. (1997) Gender differences in the outcome of an unaided smoking cessation attempt. Addict. Behav. 22:521-33.
7. Gonzales D, et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 296:47-55.
8. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. (2000) Smoking cessation with and without assistance: a population-based analysis. Am. J. Prev. Med. 18:305-11.
9. Rose JE, Behm FM, Westman EC, Kukovich P. (2006) Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. 8:89-101.
10. Rose JE, Herskovic JE, Behm FM, Westman EC. (2009) Precessation treatment with nicotine skin patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob. Res. 9:1067-75.
11. Shiffman S, Ferguson SG. (2008) Nicotine patch therapy prior to quitting smoking: a metaanalysis. Addiction. 103:557-63.
12. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008 Jan 23(1):CD000146.
13. Johnson EO, Morgan-Lopez AA, Breslau N, Hatsukami DK, Bierut LJ. (2008) Test of measurement invariance of the FTND across demographic groups: assessment, effect size, and prediction of cessation. Drug Alcohol Depend. 93:260-70.
14. Jorenby DE, et al. (1995) Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 274:1347-52.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2002;(4):CD000146.
16. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. (2006) Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res. Hum. Genet. 9:64-72.
17. Uhl GR, et al. (2007) Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 8:10.
18. Uhl GR, et al. (2008) Molecular genetics of successful smoking cessation: convergent genomewide association study results. Arch. Gen. Psychiatry. 65:683-93.
19. Goldstein DB. (2009) Common genetic variation and human traits. N. Engl. J. Med. 360:1696-8.
20. Hirschhorn JN.(2009) Genomewide association studies-illuminating biologic pathways. N. Engl. J. Med. 360:1699-701.
21. Hardy J, Singleton A. (2009) Genomewide association studies and human disease. N. Engl. J. Med. 360:1759-68.
22. Kraft P, Hunter DJ. (2009) Genetic risk prediction- are we there yet? N. Engl. J. Med. 360:1701-3.
23. Fagerström KO, et al. (1996) Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokers. Tob. Control. 5:52-6.
24. Johnson C, et al. (2006) Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141:844-53.
25. Liu QR, et al. (2006) Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141B:918-25.
26. Liu QR, et al. (2005) Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc. Natl. Acad. Sci. U. S. A. 102:11864-9.
27. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. (2001) Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am. J. Hum. Genet. 69:1290-300.
28. Purcell S, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559-75.
29. Uhl GR, Drgon T, Li CY, Johnson C, Liu QR. (2009) Smoking and smoking cessation in disadvantaged women: assessing genetic contributions. Drug Alcohol Depend. 104 Suppl 1:S58-63.
30. Uhl GR, Drgon T, Johnson C, Rose JE. (2009) Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. Pharmacogenomics J. 9:111-5.
31. Drgon T, et al. (2009) Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol. Med. 15:21-7.
32. Drgon T, et al. (2009) Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol. Med. 15:268-74
33. Igarashi A, Takuma H, Fukuda T, Tsutani K. (2009) Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics. 27:247-61.
34. Hoogendoorn M, Welsing P, Rutten-van Molken MP. (2008) Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr. Med. Res. Opin. 24:51-61.
35. Kuehn BM. (2009) Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA. 301:1007-8.
36. Becker KM, Rose JE, Albino AP. (2008) A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob. Res. 10:1139-48.
37. Botkin JR, et al. (2010) Outcomes of interest in evidence-based evaluations of genetic tests. Genet. Med. 12:228-35.
38. Chung WK. (2007) Implementation of genetics to personalize medicine. Gend. Med. 4:248-65.